ArticleScientific reports2025
A nomogram for predicting the risk of tigecycline-associated drug-induced liver injury in a Chinese population.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and external validation of a machine learning model for predicting tigecycline-associated drug-induced liver injury.iScience · 2026Article
- Predicting tigecycline-related adverse events in infected patients: a machine learning approach with clinical interpretability.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to identify risk factors more comprehensively and develop the first nomogram for predicting tigecycline-associated drug induced liver injury (DILI) in a Chinese population. Patients who underwent tigecycline treatment from January 1, 2021, to July 31, 2024, at the Affiliated Hospital of Jining Medical University were included in this retrospective study. Candidate variables were selected using least absolute shrinkage and selection operator (Lasso) regression and support vector machine recursive feature elimination (SVM-RFE), followed by univariate and multivariate logistic regression to identify independent risk factors, which were visualized in a nomogram. Nomogram model performance was evaluated via the area under the receiver operating characteristic curve (AUC). A total of 357 patients were enrolled, including 73 patients (20.4%) diagnosed with DILI, and 284 patients (79.6%) without. Fourteen intersected variables were screened through Lasso regression and SVM-RFE method. Seven variables were identified as independent risk factors and were used to construct prediction nomogram model. The AUC values of 0.82 (95% CI: 0.76-0.88) in the training cohort and 0.80 (95% CI: 0.70-0.89) indicated the nomogram model had satisfactory prediction ability. Furthermore, decision curve analysis (DCA) revealed that the nomogram provided a significant net benefit in the identifying patients at high risk of tigecycline-associated DILI. This study was the first to identify patients treated with voriconazole, with a history of malignant tumors, in a state of septic shock, and with intra-abdominal infections were at a significantly elevated risk of developing tigecycline-associated DILI. The constructed nomogram demonstrated a high level of accuracy, showcasing substantial potential to aid clinicians in pinpointing risk factors and implementing preventive measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.